维普期刊资源整合服务平台（V6.5）

42篇 您的检索式：作者名="HARTI A"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Odontiod laderal mass asymmetry:do We over - investigate 显示文摘	Harty J A Lenehan B O' Rourke SK	2005	Emerg Med J2005，22，：	1
2	Predicting range of motion after total knee arthroplasty显示文摘	Ritter M A Harty L D Davis K E etal	2003	J Bone Joint Surg Am2003，85，7：	1
3	Medial screws and cement: a possible mechanical augmentation in total knee arthroplas- ty显示文摘	Ritter M A Harty L D	2004	J Arthroplasty2004，19，5：	1
4	Simultaneous Bilateral Versus Unilateral Total Hip Arthroplasty :An Outcomes Analysis 显示文摘	Berend M E Ritter M A Harty L D	2005	Journal of Arthroplasty2005，20，4：	1
5	Influenza A virus-induced apoptosis in bronchiolar epithelial (NCI-H292)cells limits pro-inflammatory cytokine release显示文摘	Edward W A Harty S Clivc S	2003	J Gen Virol2003，84，：	1
6	A simple and rapid method for spectrophotometrie determ- ination of bromate in bread显示文摘	HARTI J E RAHALI Y BENMOUSSA A	2011	Environ Sci2011，2，1：	1
7	Viral vector vaccines make memory T cells against malaria显示文摘	Reyes-Sandoval A Harty JT Todryk SM		0，，02：	1
8	Proteome analysis of Streptococcus mutans metabolic phenotype during acid tolerance 显示文摘	Len A Harty D Jacques N	2004	Microbiology2004，150，5：	1
9	A clinical comparison of the anterolateral and posterolateral approaches to the hip显示文摘	RITTER M A HARTY L D KEATING M E	2001	Clin Orthop Rdat Res2001，，385：	1
10	Wheeze, eczema and rhinitis in 6-7year old Irish schoolchildren显示文摘	Harty SB Sheridan A Howell F	2003	Ir Med J2003，96，4：	1
11	CD81 T cell effector mechanisms in resistance to infection显示文摘	Harty J T Tvinnereim A R White D W	2000	Annu Rev Immunol2000，18，：	1
12	Modulation of Hepatocyte Protein Synthesis During Co-cultivation with Macrophage-rich Peritoneal Cells in Vitro显示文摘	Keller G A West M A Harty JT		Arch Surg0，120，：	1
13	The theory of capital structure显示文摘	Hartis M Raviv A	1991	Journal ot Finance1991，，46：	1
14	Effects of crude oil on the supralittoral meiofauna of a sandy beach显示文摘	McLACHLAN A HARTY B	1982	Marine Environmental Research1982，7，1：	1
15	Endogenous Natriurefic Peptides Participate in Renal and Humoral Actions of Acute Vasopepfidase Inhibition in Experimental Mild Heart Failure显示文摘	Chen HH Lainchbury JG Harty GJ a od	2001	Hypertemion2001，38，2：	1
16	Regeneration or scarring:an immunologic perspective显示文摘	HARTY M NEFF A W KING M W	2003	Dev Dyn2003，226，2：	1
17	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.	Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch	2017	World Journal of Virology2017，6，4：	1
18	ISG15inhibits Ebola VP40VLP budding in an L-domain-dependent manner by blocking Nedd4ligase activity显示文摘	Okumura A Pitha P M Harty R N	2008	Proc Natl Acad Sci U S A2008，105，10：	1
19	A phosphorylation-dependent gating mechmlism controls the SH2 domain interactions of the She adap- tor protein显示文摘	Gorge R Schuller A C Hartis R	2008	J Mol Bid2008，377，3：	1
20	CD8+ T-cell effector mech anisms in resistance to infection显示文摘	Harty J T Tvinnereim A R White D W		0，，0：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示